Safety assessments indicated that gastrointestinal adverse situations, largely nausea and diarrhea, were being dose-dependent but frequently mild and transient. These findings set up the therapeutic window and educated dose choice for subsequent Stage 3 trials.“Noom built the process so simple and now I come to feel full, free from diet plan obse